Literature DB >> 19696168

Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.

Shikun He1, S Ram Kumar, Peng Zhou, Valery Krasnoperov, Stephen J Ryan, Parkash S Gill, David R Hinton.   

Abstract

PURPOSE: EphB4 receptor (EphB4) and its ligand (EphrinB2) play an important role in the regulation of cell adhesion, growth, and migration. The purpose of this study was to determine the effects of EphB4 blockade by soluble EphB4 (sEphB4) on retinal pigment epithelial (RPE) cell migration and proliferation, induced by platelet-derived growth factor-BB (PDGF), and to establish its relevance to proliferative vitreoretinopathy (PVR).
METHODS: The expression of EphB4 and EphrinB2 in early-passage human RPE cells and in human PVR membranes was evaluated by confocal microscopy. The effect of sEphB4 (0.1-3 microg/mL) on PDGF (20 ng/mL)-induced RPE migration and proliferation was evaluated using a modified Boyden chamber assay and an MTT assay, respectively. Attachment to basement membrane matrix and fibronectin was assayed by MTT. Phosphorylation of FAK and p42/44 mitogen-activated protein kinase (MAPK) in retinal pigment epithelium was determined by Western blot analysis after exposure to sEphB4. The effect of sEphB4 on the phosphorylation of EphB4/EphrinB2 was demonstrated with the use of immunoprecipitation assays.
RESULTS: EphrinB2 and EphB4 were expressed on human RPE cells in vitro and in cells within human PVR membranes. sEphB4 blocked EphB4 and EphrinB2 phosphorylation in RPE cells in vitro. sEphB4 reduced RPE migration in response to PDGF stimulation (P < 0.01). Similarly, sEphB4 inhibited RPE attachment and proliferation in a dose-dependent manner (P < 0.05). PDGF-induced phosphorylation of FAK and MAPK was inhibited by sEphB4.
CONCLUSIONS: EphB4 and EphrinB2 are expressed in RPE cells and PVR membranes. sEphB4 inhibits PDGF-induced RPE cell attachment, proliferation, and migration. This effect may result from the inhibition of FAK and MAPK phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19696168      PMCID: PMC2828363          DOI: 10.1167/iovs.09-3475

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  44 in total

Review 1.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

Authors:  N W Gale; G D Yancopoulos
Journal:  Genes Dev       Date:  1999-05-01       Impact factor: 11.361

Review 2.  The retinal pigment epithelium in visual function.

Authors:  Olaf Strauss
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

3.  Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization.

Authors:  Shikun He; Yi Ding; Jiehao Zhou; Valery Krasnoperov; Sergey Zozulya; S Ram Kumar; Stephen J Ryan; Parkash S Gill; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

4.  EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion.

Authors:  Mitsutoshi Nakada; Jared A Niska; Nhan L Tran; Wendy S McDonough; Michael E Berens
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

5.  Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.

Authors:  April Thelemann; Filippo Petti; Graeme Griffin; Ken Iwata; Tony Hunt; Tina Settinari; David Fenyo; Neil Gibson; John D Haley
Journal:  Mol Cell Proteomics       Date:  2005-01-17       Impact factor: 5.911

6.  Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells.

Authors:  Stefanie Meyer; Christian Hafner; Markus Guba; Stefanie Flegel; Edward K Geissler; Bernd Becker; Gudrun E Koehl; Evelyn Orsó; Michael Landthaler; Thomas Vogt
Journal:  Int J Oncol       Date:  2005-11       Impact factor: 5.650

7.  EphB4 expression and biological significance in prostate cancer.

Authors:  Guangbin Xia; S Ram Kumar; Rizwan Masood; Sutao Zhu; Ramchandra Reddy; Valery Krasnoperov; David I Quinn; Susan M Henshall; Robert L Sutherland; Jacek K Pinski; Siamak Daneshmand; Maurizio Buscarini; John P Stein; Chen Zhong; Daniel Broek; Pradip Roy-Burman; Parkash S Gill
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

8.  A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion.

Authors:  Stephan Hoffmann; Shikun He; Manlin Jin; Marianne Ehren; Peter Wiedemann; Stephen J Ryan; David R Hinton
Journal:  BMC Ophthalmol       Date:  2005-06-29       Impact factor: 2.209

9.  Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.

Authors:  David O Zamora; Michael H Davies; Stephen R Planck; James T Rosenbaum; Michael R Powers
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-06       Impact factor: 4.799

Review 10.  Eph receptor tyrosine kinases in tumor and tumor microenvironment.

Authors:  Dana Brantley-Sieders; Sonja Schmidt; Monica Parker; Jin Chen
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  18 in total

1.  Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.

Authors:  Valery Krasnoperov; S Ram Kumar; Eric Ley; Xiuqing Li; Jeffrey Scehnet; Ren Liu; Sergey Zozulya; Parkash S Gill
Journal:  Am J Pathol       Date:  2010-02-04       Impact factor: 4.307

2.  Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization.

Authors:  Jing Du; Wei Zhao; Yusheng Wang; Yan Cai
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-04       Impact factor: 2.671

3.  Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy.

Authors:  Shikun He; Ernesto Barron; Keijiro Ishikawa; Hossein Nazari Khanamiri; Chris Spee; Peng Zhou; Satoru Kase; Zhuoshi Wang; Laurie Diane Dustin; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-08       Impact factor: 4.799

4.  PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.

Authors:  M Imran Aslam; Jinu Abraham; Atiya Mansoor; Brian J Druker; Jeffrey W Tyner; Charles Keller
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

5.  Involvement of pigment epithelium-derived factor, docosahexaenoic acid and neuroprotectin D1 in corneal inflammation and nerve integrity after refractive surgery.

Authors:  S Kenchegowda; J He; H E P Bazan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-05-10       Impact factor: 4.006

Review 6.  Eph/ephrin signaling in cell-cell and cell-substrate adhesion.

Authors:  Arvinder Singh; Emily Winterbottom; Ira O Daar
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

7.  Enhanced PKCδ and ERK signaling mediate cell migration of retinal pigment epithelial cells synergistically induced by HGF and EGF.

Authors:  Yu Jung Chen; Rong Kung Tsai; Wen Chen Wu; Ming Shan He; Ying-Hsien Kao; Wen Sheng Wu
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

8.  An automated cell-counting algorithm for fluorescently-stained cells in migration assays.

Authors:  Baraa K Al-Khazraji; Philip J Medeiros; Nicole M Novielli; Dwayne N Jackson
Journal:  Biol Proced Online       Date:  2011-10-19       Impact factor: 3.244

9.  Zebularine suppresses TGF-beta-induced lens epithelial cell-myofibroblast transdifferentiation by inhibiting MeCP2.

Authors:  Peng Zhou; Yi Lu; Xing-Huai Sun
Journal:  Mol Vis       Date:  2011-10-19       Impact factor: 2.367

10.  LGR4 Is a Direct Target of MicroRNA-34a and Modulates the Proliferation and Migration of Retinal Pigment Epithelial ARPE-19 Cells.

Authors:  Qiang Hou; Linglin Zhou; Jiajia Tang; Nan Ma; Ancong Xu; Jiang Tang; Dandan Zheng; Xiaogang Chen; Feng Chen; Xiang Da Dong; LiLi Tu
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.